# Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

> **NCT02524951** · PHASE1 · TERMINATED · sponsor: **Northwell Health** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** MSI-1436C

## Key facts

- **NCT ID:** NCT02524951
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2017-07
- **Final completion:** 2018-05-14
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** lack of interest by sponsor
- **Last updated:** 2018-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02524951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02524951, "Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02524951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*